Generate Biomedicines Inc.

4 trials 1 recruiting Commercial sponsor Merged from 2 name variants

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

1 Recruiting

1 Completed trials

17 Countries active

2 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase III: 2 Phase II: 1 Phase I: 1

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Asthma 3 Idiopathic pulmonary fibrosis 1

Top IMPs

GB-0895 2 TALADEGIB 1

All trials

4 total

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1) Pending

2025-521950-41-00 Phase III 10 countries GB-0895
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1) Pending

2025-524040-35-00 Phase III 6 countries GB-0895
A Phase 1 Study to Investigate the Safety and Tolerability of the Study Drug GB-0895 in Mild to Moderate Asthma Patients or Single Dose in C… Recruiting

2023-507611-35-00 Phase I 1 country
A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients with Lung Fibr… Ended

2024-511754-41-00 Phase II 6 countries TALADEGIB

Showing 1–4 of 4 trials

← All sponsors A–Z